JOP20200050A1 - عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام - Google Patents
عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدامInfo
- Publication number
- JOP20200050A1 JOP20200050A1 JOP/2020/0050A JOP20200050A JOP20200050A1 JO P20200050 A1 JOP20200050 A1 JO P20200050A1 JO P20200050 A JOP20200050 A JO P20200050A JO P20200050 A1 JOP20200050 A1 JO P20200050A1
- Authority
- JO
- Jordan
- Prior art keywords
- angptl3
- rnai agents
- compositions
- angiopoietin
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Abstract
يتعلق الكشف الحالي بعوامل RNAi، مثلا، عوامل RNAi مزدوجة الجديلة، قادرة على تثبيط التعبير الجيني عن شبيه آنجيوبويتين 3 (المسماة أيضا ANGPTL3، ANGPL3، بروتين شبيه آنجيوبويتين 3)، وتركيبات تتضمن عوامل ANGPTL3 RNAi. تم أيضا الكشف عن طرق استخدام عوامل ANGPTL3 RNAi وتركيبات. يمكن ترافق عوامل ANGPTL3 RNAi المكشوف عنها هنا مع المركبات الترابطية المستهدفة لتسهيل التوصيل إلى الخلايا، شاملة إلى خلايا الكبد. تم وصف تركيبات صيدلانية تتضمن واحد أو أكثر من عوامل ANGPTL3 RNAi، اختياريا مع واحد أو أكثر من علاجات إضافية. يقوم توصيل عوامل ANGPTL3 RNAi في الكائن الحي بتوفير تثبيط التعبير الجيني عن ANGPTL3، ويمكن أن تؤدي إلى مركبات تراي جليسريد أقل و/أو مستويات الكوليسترول في الخاضع. يمكن استخدام عوامل RNAi في طرق علاج الأمراض والاضطرابات المرتبطة بـ ANGPTL3، شاملة الأمراض القلبية الأيضية مثل زيادة جليسريدات الدم الثلاثية وارتفاع دهون الدم. الشكل 1A
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558819P | 2017-09-14 | 2017-09-14 | |
US201762583919P | 2017-11-09 | 2017-11-09 | |
US201862651284P | 2018-04-02 | 2018-04-02 | |
US201862694976P | 2018-07-07 | 2018-07-07 | |
PCT/US2018/050848 WO2019055633A1 (en) | 2017-09-14 | 2018-09-13 | RNAI AGENTS AND COMPOSITIONS FOR INHIBITING ANALOGUE EXPRESSION OF ANGIOPOIETIN 3 (ANGPTL3) AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200050A1 true JOP20200050A1 (ar) | 2020-03-05 |
Family
ID=65630620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0050A JOP20200050A1 (ar) | 2017-09-14 | 2018-09-13 | عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام |
Country Status (22)
Country | Link |
---|---|
US (2) | US10995335B2 (ar) |
EP (1) | EP3681513A4 (ar) |
JP (2) | JP7281452B2 (ar) |
KR (1) | KR20200044837A (ar) |
CN (2) | CN117701562A (ar) |
AU (1) | AU2018331383A1 (ar) |
BR (1) | BR112020003126A2 (ar) |
CA (1) | CA3074320A1 (ar) |
CL (1) | CL2020000666A1 (ar) |
CO (1) | CO2020001740A2 (ar) |
EC (1) | ECSP20018305A (ar) |
IL (1) | IL273173A (ar) |
JO (1) | JOP20200050A1 (ar) |
MX (1) | MX2020001912A (ar) |
PE (1) | PE20201287A1 (ar) |
PH (1) | PH12020500309A1 (ar) |
SG (1) | SG11201912188RA (ar) |
TN (1) | TN2020000038A1 (ar) |
TW (1) | TWI823866B (ar) |
UY (1) | UY37881A (ar) |
WO (1) | WO2019055633A1 (ar) |
ZA (1) | ZA202103669B (ar) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012272970A1 (en) | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
EP3506913A4 (en) * | 2016-09-02 | 2020-06-10 | Arrowhead Pharmaceuticals, Inc. | TARGETING LIGANDS |
RS63836B1 (sr) | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
EP4051795A1 (en) | 2019-11-01 | 2022-09-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
JP2023502038A (ja) | 2019-11-13 | 2023-01-20 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | アンギオテンシノーゲン(agt)関連障害を処置するための方法および組成物 |
BR112022011417A2 (pt) | 2019-12-13 | 2022-08-30 | Alnylam Pharmaceuticals Inc | Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas |
TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法 |
JP2023514336A (ja) | 2020-02-18 | 2023-04-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法 |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
JP2023516095A (ja) | 2020-03-06 | 2023-04-17 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法 |
KR20220156880A (ko) * | 2020-03-18 | 2022-11-28 | 다이서나 파마수이티컬, 인크. | Angptl3 발현을 저해하기 위한 조성물 및 방법 |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
US20210301294A1 (en) * | 2020-03-26 | 2021-09-30 | Arrowhead Pharmaceuticals, Inc. | RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use |
EP4127168A1 (en) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
BR112022021813A2 (pt) | 2020-04-27 | 2023-01-17 | Alnylam Pharmaceuticals Inc | Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas |
IL297680A (en) | 2020-04-30 | 2022-12-01 | Alnylam Pharmaceuticals Inc | IRNA compounds complement factor b (cfb) and methods of using them |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
EP4168546A1 (en) | 2020-06-18 | 2023-04-26 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
EP4331608A1 (en) * | 2020-09-30 | 2024-03-06 | Nanopeptide (Qingdao) Biotechnology Ltd. | Target ligand |
JP2023544413A (ja) | 2020-10-05 | 2023-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法 |
JP2023546103A (ja) * | 2020-10-16 | 2023-11-01 | サノフイ | Angptl3を阻害するための新規のrna組成物および方法 |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
MX2023005490A (es) | 2020-11-13 | 2023-05-23 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso. |
WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
CN117222739A (zh) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | 朊病毒蛋白(prnp)irna组合物和其使用方法 |
AU2022226098A1 (en) | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
BR112023019981A2 (pt) | 2021-03-29 | 2023-12-12 | Alnylam Pharmaceuticals Inc | Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
BR112023022284A2 (pt) | 2021-04-26 | 2023-12-26 | Alnylam Pharmaceuticals Inc | Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma |
EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
EP4347823A1 (en) | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP4347822A2 (en) | 2021-06-04 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
AR126070A1 (es) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4) |
WO2023278576A1 (en) | 2021-06-30 | 2023-01-05 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
WO2023003922A1 (en) | 2021-07-21 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
IL309905A (en) | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | IRNA compositions in β-catenin (CTNNB1) and methods of using them |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
KR20240042004A (ko) | 2021-08-03 | 2024-04-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법 |
AU2022324003A1 (en) | 2021-08-04 | 2024-02-08 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) |
KR20240045300A (ko) | 2021-08-13 | 2024-04-05 | 알닐람 파마슈티칼스 인코포레이티드 | 인자 XII (F12) iRNA 조성물 및 이의 사용 방법 |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
AU2022352799A1 (en) * | 2021-09-23 | 2024-03-21 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) protein |
WO2023064530A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
TW202334418A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓(HTT)iRNA劑組成物及其使用方法 |
CA3235672A1 (en) * | 2021-11-29 | 2023-06-01 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein |
US20230193271A1 (en) | 2021-12-22 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors |
WO2023134705A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海金中锘美生物医药科技有限公司 | 抑制angptl3表达的rna干扰剂及其用途 |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
CN116987696A (zh) * | 2022-08-04 | 2023-11-03 | 北京福元医药股份有限公司 | 用于抑制angptl3基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
WO2024032608A1 (zh) * | 2022-08-08 | 2024-02-15 | 大睿生物医药科技(上海)有限公司 | 调控ANGPTL3基因活性的siRNA分子 |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
CN1433482A (zh) | 1999-12-09 | 2003-07-30 | 三共株式会社 | 高脂血症的治疗或预防剂的检验方法 |
MXPA04004609A (es) | 2001-11-16 | 2004-08-12 | Genentech Inc | Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina. |
CA2500224C (en) * | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
US20070276134A1 (en) * | 2006-05-24 | 2007-11-29 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and organic cations |
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
KR20120102630A (ko) * | 2009-11-26 | 2012-09-18 | 쿠아크 파마수티칼스 인코퍼레이티드 | 말단 치환체를 포함하는 에스아이 알엔에이 화합물 |
AU2011203986C1 (en) * | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
MX2012009178A (es) | 2010-02-24 | 2012-11-30 | Arrowhead Res Corp | Composiciones para liberacion dirigida de arnsi. |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
AU2012272970A1 (en) * | 2011-06-21 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof |
WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
EA201490993A1 (ru) * | 2011-11-18 | 2014-09-30 | Элнилэм Фармасьютикалз, Инк. | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи |
MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
US20150299696A1 (en) * | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
WO2015100394A1 (en) | 2013-12-24 | 2015-07-02 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
EP3137605B1 (en) | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
NZ767118A (en) | 2014-08-20 | 2024-02-23 | Alnylam Pharmaceuticals Inc | Modified double-stranded rna agents |
WO2016154127A2 (en) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
CA2982450A1 (en) * | 2015-04-13 | 2016-10-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
CN113797348A (zh) | 2016-03-07 | 2021-12-17 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
MA45340A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques du récepteur des androgènes et leurs utilisations |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
EP3506913A4 (en) | 2016-09-02 | 2020-06-10 | Arrowhead Pharmaceuticals, Inc. | TARGETING LIGANDS |
-
2018
- 2018-09-13 CN CN202311448750.0A patent/CN117701562A/zh active Pending
- 2018-09-13 SG SG11201912188RA patent/SG11201912188RA/en unknown
- 2018-09-13 KR KR1020207007014A patent/KR20200044837A/ko not_active Application Discontinuation
- 2018-09-13 CN CN201880073901.XA patent/CN111343994B/zh active Active
- 2018-09-13 EP EP18855310.1A patent/EP3681513A4/en active Pending
- 2018-09-13 MX MX2020001912A patent/MX2020001912A/es unknown
- 2018-09-13 AU AU2018331383A patent/AU2018331383A1/en active Pending
- 2018-09-13 JO JOP/2020/0050A patent/JOP20200050A1/ar unknown
- 2018-09-13 PE PE2020000671A patent/PE20201287A1/es unknown
- 2018-09-13 BR BR112020003126-7A patent/BR112020003126A2/pt unknown
- 2018-09-13 US US16/130,377 patent/US10995335B2/en active Active
- 2018-09-13 TN TNP/2020/000038A patent/TN2020000038A1/en unknown
- 2018-09-13 JP JP2020514926A patent/JP7281452B2/ja active Active
- 2018-09-13 CA CA3074320A patent/CA3074320A1/en active Pending
- 2018-09-13 WO PCT/US2018/050848 patent/WO2019055633A1/en active Application Filing
- 2018-09-14 UY UY0001037881A patent/UY37881A/es unknown
- 2018-09-14 TW TW107132397A patent/TWI823866B/zh active
-
2020
- 2020-02-11 PH PH12020500309A patent/PH12020500309A1/en unknown
- 2020-02-14 CO CONC2020/0001740A patent/CO2020001740A2/es unknown
- 2020-03-09 IL IL273173A patent/IL273173A/en unknown
- 2020-03-12 EC ECSENADI202018305A patent/ECSP20018305A/es unknown
- 2020-03-13 CL CL2020000666A patent/CL2020000666A1/es unknown
-
2021
- 2021-04-15 US US17/231,479 patent/US20210238602A1/en active Pending
- 2021-05-28 ZA ZA2021/03669A patent/ZA202103669B/en unknown
-
2023
- 2023-02-27 JP JP2023028733A patent/JP2023054368A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12020500309A1 (en) | 2021-01-25 |
CN111343994B (zh) | 2023-11-21 |
CN117701562A (zh) | 2024-03-15 |
CL2020000666A1 (es) | 2020-08-14 |
UY37881A (es) | 2019-03-29 |
IL273173A (en) | 2020-04-30 |
US10995335B2 (en) | 2021-05-04 |
CO2020001740A2 (es) | 2020-05-29 |
TWI823866B (zh) | 2023-12-01 |
EP3681513A1 (en) | 2020-07-22 |
KR20200044837A (ko) | 2020-04-29 |
TW201922264A (zh) | 2019-06-16 |
JP2023054368A (ja) | 2023-04-13 |
BR112020003126A2 (pt) | 2020-10-13 |
CA3074320A1 (en) | 2019-03-21 |
CN111343994A (zh) | 2020-06-26 |
WO2019055633A1 (en) | 2019-03-21 |
US20210238602A1 (en) | 2021-08-05 |
US20190078089A1 (en) | 2019-03-14 |
PE20201287A1 (es) | 2020-11-24 |
AU2018331383A1 (en) | 2020-04-23 |
EP3681513A4 (en) | 2021-09-22 |
MX2020001912A (es) | 2020-03-24 |
SG11201912188RA (en) | 2020-01-30 |
ZA202103669B (en) | 2023-03-29 |
JP7281452B2 (ja) | 2023-05-25 |
JP2020534268A (ja) | 2020-11-26 |
ECSP20018305A (es) | 2020-06-30 |
TN2020000038A1 (en) | 2021-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200050A1 (ar) | عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام | |
PH12020500332A1 (en) | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) | |
ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
ZA202002094B (en) | Trispecific proteins and methods of use | |
WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
PH12021550423A1 (en) | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
AU2022206685B2 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
EP4124346A3 (en) | Compositions and methods for treating diseases | |
EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
PH12019502660A1 (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
CR20200117A (es) | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso | |
EA202090717A1 (ru) | СРЕДСТВА И КОМПОЗИЦИИ РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA202090687A1 (ru) | РНКи-АГЕНТЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (APOC3) | |
EA202090234A1 (ru) | СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ | |
AR113254A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA ANGIOPOYETINA TIPO 3 (ANGPTL3) Y MÉTODOS DE USO | |
AR113454A1 (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 |